



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ezabenlimab

Cat. No.:	HY-P99610
CAS No.:	2249882-54-8
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_D value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon- γ secretion in T cells, and inhibits tumor growth in vivo ^[1] .									
IC₅₀ & Target	PD-1/PD-L1, PD-1/PD-L2, IFN- γ ^[1]									
In Vitro	<p>Ezabenlimab inhibits the interaction of PD-1 to PD-L1 and PD-L2 in CHO cells with IC_{90S} of 4.14 nM and 3.98 nM, respectively; and inhibits the interaction of PD-1 to PD-L1 and PD-L2 in cynomolgus with IC_{90S} of 5.61 nM and 7.54 nM, respectively^[1]. Ezabenlimab increases IFN-γ secretion in primary human antigen-experienced CD3-positive T cells, with an EC₅₀ value of 0.9 nM^[1].</p> <p>Ezabenlimab (200 nM) has synergistic effect with BI 754111, resulting in further increase of IFN-γ secretion^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Ezabenlimab (0.3-30 mg/kg; i.p.; single dose or twice per week or every 3 weeks) inhibits tumor progress and shows comparable anti-tumor activity in hPD-1 knock-in mouse model^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>hPD-1 knock-in mouse model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; single dose or twice per week or every 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Showed tumor growth inhibition (TGI) at day 25 dose-dependently of 99%, 101%, 91%, 48%, and 44%, respectively.</td> </tr> </table>		Animal Model:	hPD-1 knock-in mouse model ^[1]	Dosage:	0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg	Administration:	Intraperitoneal injection; single dose or twice per week or every 3 weeks	Result:	Showed tumor growth inhibition (TGI) at day 25 dose-dependently of 99%, 101%, 91%, 48%, and 44%, respectively.
Animal Model:	hPD-1 knock-in mouse model ^[1]									
Dosage:	0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg									
Administration:	Intraperitoneal injection; single dose or twice per week or every 3 weeks									
Result:	Showed tumor growth inhibition (TGI) at day 25 dose-dependently of 99%, 101%, 91%, 48%, and 44%, respectively.									

REFERENCES

[1]. Zettl M, et al. Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. *Oncoimmunology*. 2022 Jun 16;11(1):2080328.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA